San Diego / California / United States
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing technology to fuel drug discovery and clinical development of treatments for central nervous system disorders. It has five drug programs in clinical and pre-clinical development directed at large unmet medical needs and major commercial markets. ACADIA s three Phase II-stage clinical programs are ACP-103 for treatment-induced dysfunction in Parkinsons disease, ACP-103 as an adjunctive therapy for schizophrenia and ACP-104 for treatment of schizophrenia. The company also has clinical and pre-clinical development programs in the areas of neuropathic pain and glaucoma in collaboration with Allergan. ACADIA maintains headquarters and biology research facilities in San Diego and a chemistry research facility in Malmo, Sweden. It trades on NASDAQ under the symbol ACAD.
